Home GN Module Lupus Nephritis Case 7

Kidney Biopsy Interpretation

Light Microscopy, Immunofluorescence & Electron Microscopy: Pattern Recognition for Glomerular Disease

Light Microscopy Immunofluorescence Electron Microscopy Pattern-to-Disease

Quick Navigation

Specimen Adequacy Light Microscopy Immunofluorescence Electron Microscopy Pattern-to-Disease Table Special Stains

Specimen Adequacy

A kidney biopsy must contain sufficient cortical tissue to allow confident diagnosis. Inadequate samples may lead to missed focal diseases (e.g., FSGS) or underestimate disease severity.

Minimum for Diagnosis

8–10 glomeruli

Minimum glomerular count for reliable histologic diagnosis

Ideal Sample

20+ glomeruli

Especially important for focal diseases like FSGS

Cores Required

2–3 cores

Each core 1–2 cm length; 16-gauge needle standard

Clinical Pearl: FSGS lesions are focal (not all glomeruli affected) and segmental (not the entire glomerulus). With only 5 glomeruli, there is a significant chance of missing FSGS. Statistical modeling shows that ≥25 glomeruli are needed to exclude FSGS with 90% confidence if the true prevalence of affected glomeruli is 10%.

Tissue Distribution Across Studies

Study Fixative/Medium Purpose
Light Microscopy Formalin-fixed, paraffin-embedded Structural patterns, cellularity, sclerosis, fibrosis
Immunofluorescence Snap-frozen (OCT medium) Immune deposits (IgG, IgA, IgM, C3, C1q, kappa, lambda)
Electron Microscopy Glutaraldehyde-fixed Deposit location, foot process effacement, basement membrane

Light Microscopy Patterns

Proliferative Patterns

Mesangial Proliferation

Definition: Increased mesangial cells (>3 per mesangial area) and/or matrix expansion

Key diseases:

  • IgA nephropathy
  • Early lupus nephritis (Class II)
  • Diabetic nephropathy

Endocapillary Proliferation

Definition: Increased cellularity within glomerular capillary lumina (endothelial cells, monocytes, neutrophils)

Key diseases:

  • Post-infectious GN (diffuse)
  • Lupus nephritis Class III/IV
  • MPGN
  • IgA nephropathy (with activity)

Extracapillary Proliferation (Crescents)

Definition: Proliferation in Bowman’s space forming crescents; indicates severe injury with capsule rupture

Key diseases:

  • ANCA vasculitis (pauci-immune)
  • Anti-GBM disease (Goodpasture)
  • Lupus nephritis Class IV with crescents
  • Severe IgA nephropathy

Crescent Classification — Prognostic Significance

Cellular Crescent

Predominantly cells (epithelial cells, macrophages)

Prognosis: Potentially reversible with immunosuppression

→

Fibrocellular Crescent

Mix of cells and fibrosis

Prognosis: Partially reversible; intermediate prognosis

→

Fibrous Crescent

Predominantly collagen/fibrosis

Prognosis: Irreversible; represents end-stage glomerular scarring

Sclerosis Patterns

Pattern Definition Clinical Significance
Segmental Sclerosis Sclerosis involving part of the glomerular tuft FSGS (primary or secondary); perihilar variant suggests adaptive FSGS
Global Sclerosis Entire glomerulus replaced by scar tissue End-stage of any glomerular injury; >50% globally sclerosed = poor prognosis for recovery
Nodular Sclerosis Kimmelstiel-Wilson nodules (mesangial nodular expansion) Pathognomonic for diabetic nephropathy; also seen in LCDD and amyloid

Necrosis

Fibrinoid necrosis of capillary loops indicates severe, active injury. Characteristic of:

  • ANCA vasculitis (segmental necrosis)
  • Anti-GBM disease
  • Thrombotic microangiopathy (TMA)
  • Malignant hypertension

Interstitial Fibrosis & Tubular Atrophy (IFTA) — Chronicity Index

Grade % Cortex Affected Significance
Mild (Grade 1) <25% Early chronic changes; may still respond to therapy
Moderate (Grade 2) 25–50% Significant chronic damage; partial response expected
Severe (Grade 3) >50% Advanced chronicity; unlikely to recover; may be futile to treat with immunosuppression
Clinical Pearl: IFTA is the single best histologic predictor of long-term renal prognosis, regardless of the primary disease. Advanced IFTA (>50%) generally indicates irreversible damage and should prompt discussion about CKD management rather than aggressive immunosuppression.

Immunofluorescence (IF) Patterns

IF identifies the type and distribution of immune deposits. The staining pattern is the single most important diagnostic clue for classifying glomerulonephritis.

Key IF Patterns

LINEAR IgG Staining

Pattern: Smooth, continuous IgG along the GBM

Disease: Anti-GBM disease (Goodpasture syndrome)

Mechanism: Antibodies directed against the alpha-3 chain of type IV collagen in the GBM

Also seen: Diabetic nephropathy (non-specific trapping; no clinical significance)

GRANULAR Staining

Pattern: Lumpy-bumpy, discontinuous deposits along capillary walls and/or mesangium

Diseases:

  • Membranous nephropathy (granular IgG, C3 along capillary walls)
  • Post-infectious GN (granular IgG, C3 — "starry sky")
  • MPGN
  • Lupus nephritis

FULL HOUSE Staining

Pattern: IgG, IgA, IgM, C3, and C1q all positive

Disease: Lupus nephritis (virtually pathognomonic)

Significance: C1q positivity is particularly characteristic of SLE; helps distinguish from other immune complex diseases

PAUCI-IMMUNE (Negative IF)

Pattern: Little or no immunoglobulin or complement staining

Diseases:

  • ANCA-associated vasculitis (GPA, MPA, EGPA)

Significance: Crescentic GN with negative IF strongly suggests ANCA vasculitis; check serum ANCA (MPO, PR3)

IgA DOMINANT Staining

Pattern: IgA as the dominant or co-dominant immunoglobulin, primarily mesangial

Diseases:

  • IgA nephropathy (Berger disease)
  • IgA vasculitis (Henoch-Schönlein purpura) nephritis

Note: May also have C3 and IgG co-staining; C1q is typically absent (classical pathway not activated)

Light Chain Restriction

Pattern: Monoclonal kappa OR lambda staining (not both)

Diseases:

  • Light chain deposition disease (LCDD)
  • AL amyloidosis
  • Proliferative GN with monoclonal Ig deposits (PGNMID)

Significance: Monoclonal restriction = paraprotein-related disease; search for underlying hematologic malignancy

Electron Microscopy: Deposit Location

EM localizes immune deposits relative to the glomerular basement membrane (GBM) and evaluates podocyte foot processes. Deposit location is the single most specific finding for disease classification.

Deposit Locations and Disease Correlation

Subepithelial

Between GBM and podocytes

  • Membranous nephropathy (diffuse)
  • Post-infectious GN ("humps")
  • Lupus Class V
Subendothelial

Between GBM and endothelium

  • Lupus nephritis Class III/IV
  • MPGN Type I
  • Wire-loop lesions (massive subendothelial deposits in lupus)
Mesangial

Within the mesangium

  • IgA nephropathy
  • Lupus Class I/II
  • Early diabetic nephropathy
Intramembranous

Within the GBM itself

  • Dense deposit disease (C3 GN / MPGN Type II)
  • Ribbon-like dense transformation of the GBM

Foot Process Effacement

Diffuse Effacement (>80%)

Indicates podocytopathy with massive proteinuria

  • Minimal Change Disease: Diffuse effacement with NO deposits, NO proliferation, NO sclerosis
  • Primary FSGS: Diffuse effacement with segmental sclerosis

Focal/Segmental Effacement

Seen overlying areas of immune deposits or sclerosis

  • Secondary FSGS (adaptive): effacement 30–60%
  • Membranous nephropathy: effacement over deposits
  • Immune complex GN: focal effacement near deposits
High-Yield Distinction — MCD vs. FSGS on EM: In MCD, foot process effacement is diffuse (>80%) but the biopsy otherwise appears normal (no immune deposits, no sclerosis). In primary FSGS, diffuse effacement is present along with segmental sclerosis on LM. In secondary/adaptive FSGS, effacement is typically only 30–60% and limited to areas near sclerotic segments.

Wire-Loop Lesions (Lupus Nephritis)

Wire-loop lesions represent massive subendothelial immune complex deposits that thicken the capillary wall, making it appear rigid and refractile on LM (resembling a wire loop).

  • Virtually pathognomonic for: Lupus nephritis Class IV (diffuse proliferative)
  • On EM: Massive electron-dense subendothelial deposits
  • Clinical significance: Indicates severe, active disease requiring aggressive immunosuppression

Comprehensive Pattern-to-Disease Correlation

Disease Light Microscopy Immunofluorescence Electron Microscopy Key Diagnostic Feature
Minimal Change Disease Normal glomeruli Negative Diffuse foot process effacement; no deposits Normal LM + diffuse FPE on EM
FSGS (Primary) Segmental sclerosis (may be focal) Nonspecific IgM/C3 trapping in sclerotic areas Diffuse FPE (>80%) Segmental sclerosis + diffuse FPE
Membranous Nephropathy GBM thickening, spikes on silver stain Granular IgG, C3 along capillary walls Subepithelial deposits with GBM reaction (stages I–IV) Subepithelial deposits; anti-PLA2R antibody
IgA Nephropathy Mesangial proliferation (variable) Dominant IgA in mesangium (±C3, IgG) Mesangial electron-dense deposits Dominant mesangial IgA on IF
Post-Infectious GN Diffuse endocapillary proliferation; neutrophil infiltration Granular IgG, C3 ("starry sky") Subepithelial "humps" Subepithelial humps + starry sky IF
Lupus Nephritis III/IV Endocapillary proliferation, crescents, wire-loop lesions "Full house" (IgG, IgA, IgM, C3, C1q) Subendothelial deposits (tubuloreticular inclusions) Full house IF + subendothelial deposits
Lupus Nephritis V GBM thickening (mimics membranous) Full house Subepithelial deposits Membranous pattern + full house IF
Anti-GBM Disease Crescentic GN, fibrinoid necrosis Linear IgG along GBM No electron-dense deposits Linear IgG + crescents
ANCA Vasculitis Focal segmental necrosis, crescents Pauci-immune (negative or scant) No or scant immune deposits Crescentic GN + pauci-immune IF
MPGN Type I Mesangial interposition, "tram-tracking" of GBM Granular C3, IgG; variable Subendothelial deposits, mesangial interposition Tram-tracking + subendothelial deposits
Dense Deposit Disease MPGN pattern or mesangial proliferative C3 dominant (C3 glomerulopathy) Intramembranous dense osmiophilic transformation Ribbon-like intramembranous dense deposits
Diabetic Nephropathy Kimmelstiel-Wilson nodules, GBM thickening, mesangial expansion Linear IgG (non-specific trapping), albumin GBM thickening, mesangial expansion Nodular mesangial sclerosis (clinical context)
Amyloidosis (AL/AA) Amorphous eosinophilic deposits; Congo red positive with apple-green birefringence Lambda or kappa restriction (AL) or negative (AA) Non-branching fibrils 8–12 nm Congo red birefringence + 8–12 nm fibrils
Fibrillary GN MPGN or mesangial pattern Polyclonal IgG, C3; DNAJB9 positive Randomly arranged fibrils 16–24 nm Fibrils larger than amyloid (16–24 nm); Congo red negative

Special Stains and Techniques

Stain Highlights Clinical Use
Congo Red Amyloid fibrils; apple-green birefringence under polarized light Diagnosis of amyloidosis (AL, AA, ALECT2). Must examine under polarized light to confirm birefringence.
Jones Methenamine Silver (JMS) Basement membranes; GBM spikes and double contours Membranous nephropathy (spikes), MPGN (tram-tracking), GBM abnormalities
PAS (Periodic Acid-Schiff) Glycoproteins, basement membranes, mesangial matrix GBM thickening (diabetic, membranous), mesangial expansion, tubular basement membranes
Trichrome (Masson) Collagen (blue/green), immune deposits (red/fuchsinophilic) Quantify interstitial fibrosis; identify fuchsinophilic deposits (immune complex, fibrin)
H&E General architecture, cellularity Initial assessment of glomerular, tubular, interstitial, and vascular compartments
Thioflavin T Amyloid (fluorescent) More sensitive than Congo red for small amyloid deposits
Congo Red — High-Yield: Amyloid deposits appear salmon-pink on H&E and show apple-green birefringence under polarized light after Congo red staining. This is pathognomonic for amyloidosis. Always request Congo red when amyloid is suspected (nephrotic syndrome in older patient, cardiac involvement, neuropathy, hepatomegaly).

References

  1. Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD Atlas of Renal Pathology: Renal Biopsy Specimen Processing and Interpretation. Am J Kidney Dis. 2016;67(6):e33-e34. PubMed
  2. Sethi S, Haas M, Markowitz GS, et al. Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. J Am Soc Nephrol. 2016;27(5):1278-1287. PubMed
  3. Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the ISN/RPS classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789-796. PubMed
  4. Trimarchi H, Barratt J, Cattran DC, et al. Oxford Classification of IgA nephropathy 2016: an update. Kidney Int. 2017;91(1):1-8. PubMed
  5. D'Agati VD, Fogo AB, Bruijn JA, et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004;43(2):368-382. PubMed
  6. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. PubMed
  7. Whittier WL, Korbet SM. Timing of complications in percutaneous renal biopsy. J Am Soc Nephrol. 2004;15(1):142-147. PubMed
  8. Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20(9):2055-2064. PubMed
  9. Nasr SH, Valeri AM, Cornell LD, et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol. 2011;6(4):775-784. PubMed
  10. Corapi KM, Chen JLT, Balk EM, Gordon CE. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis. 2012;60(1):62-73. PubMed

Andrew Bland, MD, MBA, MS | University of Dubuque PA Program | Urine Nephrology Now

© 2025 | For educational purposes only